🔗 Permalink

Inventor profile of:

Douglas Alan Lorenz

City:

Bend, Oregon

Country:

United States

Published Applications:

Last publication date:

2025-03-20

Top Assignees for applications by Douglas Alan Lorenz

The entities that hold a legal rights for patent applications filed by inventor Lorenz Douglas Alan:

Glialogix, Inc. 5 San Anselmo, CA United States
ASTELLAS PHARMA INC. 4 Tokyo, Japan
Medivation Prostate Therapeutics LLC 3 New York, NY United States
BEND RESEARCH 2 Bend, OR United States
MEDIVATION PROSTATE THERAPEUTICS, INC. 2 San Francisco, CA United States
Glialogix, Inc. 1 Greenbrae, CA United States
BEND RESEARCH, INC. 1 Bend, OR United States
ASTELLAS PHARMA INC. 1 Tokuo, Japan
CYMABAY THERAPEUTICS, INC. 1 Hayward, CA United States
CymaBay Therapeutics, Inc. 1 Newark, CA United States
PFIZER INC. 1 New York, NY United States
Glialogix, Inc. 1 Larkspur, CA United States

Recent patent applications by Lorenz Douglas Alan

Douglas Alan Lorenz from Bend, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-03-20

US20250090465A1

Human necessities

Formulations of Enzalutamide

#2 | 2025-02-13

US20250049721A1

Human necessities

Formulations of Enzalutamide

#3 | 2023-07-06

US20230210778A1

Human necessities

Formulations of enzalutamide

#4 | 2023-04-20

US20230122911A1

Human necessities

FORMULATIONS OF ENZALUTAMIDE

#5 | 2020-02-27

US20200060976A1

Human necessities

FORMULATIONS OF ENZALUTAMIDE

#6 | 2019-07-11

US20190209476A1

Human necessities

FORMULATIONS OF ENZALUTAMIDE

#7 | 2019-01-17

US20190015431A1

Human necessities

Compositions and methods for the treatment of neurodegenerative and other diseases

#8 | 2017-08-10

US20170224624A1

Human necessities

FORMULATIONS OF ENZALUTAMIDE

#9 | 2017-06-15

US20170165279A1

Human necessities

Compositions and methods for the treatment of neurodegenerative and other diseases

#10 | 2017-03-23

US20170079991A1

Human necessities

Compositions and methods for the treatment of neurodegenerative and other diseases

#11 | 2017-03-23

US20170079990A1

Human necessities

Compositions and methods for the treatment of neurodegenerative and other diseases

#12 | 2017-02-02

US20170027910A1

Human necessities

FORMULATIONS OF ENZALUTAMIDE

#13 | 2016-07-28

US20160213618A1

Human necessities

Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

#14 | 2014-12-25

US20140378517A1

Human necessities

FORMULATIONS OF ENZALUTAMIDE

#15 | 2014-08-07

US20140221321A1

Human necessities

Compositions and methods for the treatment of neurodegenerative and other diseases

#16 | 2014-06-26

US20140179749A1

Human necessities

FORMULATIONS OF ENZALUTAMIDE

#17 | 2014-04-10

US20140100256A1

Human necessities

FORMULATIONS OF ENZALUTAMIDE

#18 | 2011-12-29

US20110318418A1

Human necessities

Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

#19 | 2010-02-04

US20100029667A1

Human necessities

Spray dried formulation

#20 | 2008-11-06

US20080274192A1

Human necessities

Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor

#21 | 2005-06-16

US20050129772A1

Chemistry; metallurgy

Compositions comprising an HIV protease inhibitor

InventorID:

720225 ⎘